NCT05069935View on ClinicalTrials.gov

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 15, 2021

Primary Completion Date

August 11, 2023

Study Completion Date

August 11, 2023

Conditions
Solid Tumor, Adult
Interventions
DRUG

FT538

FT538 is an allogeneic natural killer (NK)-cell immunotherapy

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

COMBINATION_PRODUCT

Monoclonal antibody - Dose Escalation

either avelumab, trastuzumab or cetuximab

COMBINATION_PRODUCT

Monoclonal antibody - Dose Expansion

either avelumab, atezolizumab, nivolumab, pembrolizumab, trastuzumab or cetuximab

Trial Locations (4)

37203

Sarah Cannon, Nashville

77030

University of Texas MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

07601

Hackensack University Medical Center, Hackensack

Sponsors

Lead Sponsor

Fate Therapeutics
All Listed Sponsors
lead

Fate Therapeutics

INDUSTRY

NCT05069935 - FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter